Literature DB >> 20041316

May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis.

Hai Wang1, Bing Guan, Qunli Shi, Henhui Ma, Hangbo Zhou, Xuan Wang, Xiaojun Zhou.   

Abstract

Metaplastic breast carcinoma (MBC) encompasses a heterogeneous group of tumors. Based upon the microarray of MBCs, these tumors showed features of basal-like carcinoma and myoepithelial differentiation. However, MBCs entity still remained unclear. So we performed a systematic research to explicit metaplastic breast carcinomas further. A panel of ER, PR, HER-2, CK5/6, CK14, P63 and EGFR were prepared for detection of MBCs, and fluorescence in situ hybridization for HER-2 gene amplification and ultrastructure observation were also performed. Sensitiveness between CK5/6 and other antibodies in diagnosis was analysed, and survival analysis was also carried out. ER, PR and HER-2 were negative. CK5/6 (12/12), CK14 (9/12), EGFR (10/12) and P63 (8/12) were positive. FISH for HER-2 displayed no amplification (ratio values < 1.8). Ultrastructure showed tonofibrils, thin filament and dense body in the cytoplasm. Significant statistical differences were detected between groups (F = 8.080, P = 0.000) of score of CK5/6, CK14, P63 and EGFR. Significant statistical differences were also detected between age and lymph node involvement and survival (χ(2) = 10.835, P = 0.004). MBCs may be actually basal-like carcinomas. In the diagnosis of MBCs, CK5/6, CK14, P63 and EGFR may be effective and CK5/6 may be more sensitive than CK14 and P63. Survival of MBCs may be associated with age and lymph node involvement. However, given the limitations of our research accumulated cases, prospective clinicopathologic studies are needed to further elucidate MBCs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20041316     DOI: 10.1007/s12032-009-9399-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  32 in total

1.  Prognostic relevance of basal cytokeratin expression in operable breast cancer.

Authors:  Piotr Potemski; Renata Kusinska; Cezary Watala; Elzbieta Pluciennik; Andrzej K Bednarek; Radzislaw Kordek
Journal:  Oncology       Date:  2006-01-12       Impact factor: 2.935

2.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

Authors:  E A Rakha; T C Putti; D M Abd El-Rehim; C Paish; A R Green; D G Powe; A H Lee; J F Robertson; I O Ellis
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

3.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 4.  Basal-like breast carcinoma: from expression profiling to routine practice.

Authors:  Emad Rakha; Jorge S Reis-Filho
Journal:  Arch Pathol Lab Med       Date:  2009-06       Impact factor: 5.534

Review 5.  [Basal-like breast cancer: a review].

Authors:  Isabelle Treilleux; Blandine Morellon-Mialhe
Journal:  Ann Pathol       Date:  2009-06-12       Impact factor: 0.407

Review 6.  [Basal-like carcinoma of the breast].

Authors:  Fátima Silva; Sílvia Carvalho; Fernanda Milanezi; Fernando C Schmitt
Journal:  Acta Med Port       Date:  2008-10-24

Review 7.  Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia.

Authors:  A Karakosta; Ch Golias; A Charalabopoulos; D Peschos; A Batistatou; K Charalabopoulos
Journal:  J Exp Clin Cancer Res       Date:  2005-12

8.  Metaplastic breast carcinoma in a patient with Von Recklinghausen's disease.

Authors:  Ioannis Natsiopoulos; Aristides Chatzichristou; Ioannis Stratis; Anna Skordalaki; Nikolaos Makrantonakis
Journal:  Clin Breast Cancer       Date:  2007-04       Impact factor: 3.225

9.  Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

Authors:  Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Eugeni López-Bonet; Begoña Martín-Castillo; Sonia Del Barco; Joan Brunet; Javier A Menendez
Journal:  Int J Oncol       Date:  2008-12       Impact factor: 5.650

10.  Histological grading of breast carcinomas: a study of interobserver agreement.

Authors:  P Robbins; S Pinder; N de Klerk; H Dawkins; J Harvey; G Sterrett; I Ellis; C Elston
Journal:  Hum Pathol       Date:  1995-08       Impact factor: 3.466

View more
  2 in total

1.  Metaplastic breast cancer with chondrosarcomatous differentiation combined with concurrent bilateral breast cancer: A case report.

Authors:  Si-Yuan Yang; Yang Li; Jian-Yun Nie; Shou-Tao Yang; Xiao-Juan Yang; Mao-Hua Wang; Ji Zhang
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

2.  Metaplastic carcinoma of the breast: an immunohistochemical study.

Authors:  Fadwa J Altaf; Ghadeer A Mokhtar; Eman Emam; Rana Y Bokhary; Najlaa Bin Mahfouz; Samia Al Amoudi; Zuhoor K Al-Gaithy
Journal:  Diagn Pathol       Date:  2014-07-16       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.